Dr. Warnatz has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Medisys Health Care and Elsevier.
Soluble CD90 as a potential marker of pulmonary involvement in systemic sclerosis
Article first published online: 30 JAN 2013
Copyright © 2013 by the American College of Rheumatology
Arthritis Care & Research
Volume 65, Issue 2, pages 281–287, February 2013
How to Cite
Kollert, F., Christoph, S., Probst, C., Budweiser, S., Bannert, B., Binder, M., Sehnert, B., Voll, R. E., Warnatz, K., Zissel, G., Walker, U. A., Prasse, A. and Saalbach, A. (2013), Soluble CD90 as a potential marker of pulmonary involvement in systemic sclerosis. Arthritis Care Res, 65: 281–287. doi: 10.1002/acr.21799
- Issue published online: 30 JAN 2013
- Article first published online: 30 JAN 2013
- Accepted manuscript online: 17 JUL 2012 12:47PM EST
- Manuscript Accepted: 27 JUN 2012
- Manuscript Received: 16 NOV 2011
Vascular injury and endothelial cell (EC) activation are pathogenic hallmarks of systemic sclerosis (SSc; scleroderma). Human CD90 is highly expressed on activated ECs and can be shed from the cell surface. This study was conducted to examine whether soluble CD90 (sCD90) is elevated in the sera of patients with SSc and linked to pulmonary involvement and in particular, pulmonary arterial hypertension (PAH).
sCD90 serum concentrations were assessed in 76 patients with SSc and related to clinical data, lung function, 6-minute walk distance, echocardiography, bronchoalveolar lavage fluid, and laboratory parameters. Thirty-one healthy volunteers and 29 patients with idiopathic retroperitoneal fibrosis (IRF) served as controls.
sCD90 serum concentrations were elevated in patients with SSc compared to healthy volunteers (P = 0.001) and patients with IRF (P = 0.01). SSc patients with pulmonary fibrosis (P = 0.006) and patients with PAH (P < 0.001) had increased sCD90 serum concentrations compared to patients without the respective pulmonary manifestation of SSc. sCD90 levels correlated with diffusing capacity for carbon monoxide (n = 65; r = −0.348, P = 0.005) and systolic pulmonary artery pressure (n = 53; r = 0.469, P < 0.001). Receiver operating characteristic curve testing determined an optimal cutoff value of ≥626 ng/ml with a sensitivity of 68% and a specificity of 83% for PAH (area under the curve 0.773, 95% confidence interval 0.648–0.898; P < 0.001).
sCD90 concentrations were increased in the sera of SSc patients, particularly in patients with vascular involvement of the lungs. These data suggest that sCD90 should be further evaluated as a marker for diagnosis of PAH in SSc.